Adlai Share Price

Adlai Share Price

NASDAQ: ANL | Others
$8.60
-$0.46 (-5.13%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Adlai Stock Performance

Open
$8.79
Prev. Close
$9.06
Circuit Range
N/A
Day Range
$8.39 - $8.98
Year Range
$0.91 - $17.16
Volume
17,046
Average Traded
$8.64

Adlai Share Price Today

As of 21 November 2026, Adlai Nortye Group Ltd.'s share price is $8.60. The stock opened at $8.79, compared to its previous close of $9.06. During today's trading session, Adlai Nortye Group Ltd.'s share price traded between $8.39 and $8.98, with an average price of $8.69. Over the past 52 weeks, the stock has recorded a high of $17.16 and a low of $0.91. In terms of performance, Adlai Nortye Group Ltd.'s share price has declined by 28.03% over the last six months and is up 503.51% on a year-on-year basis.

Adlai Share Price Chart

Line chart of the Adlai price trend over the selected period. The price fell overall, ranging from 8.39 to 8.98, ending at 8.60.
$8.39$8.98
L
Show Current Price
H

Adlai Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$5.00B
Return On Equity (TTM)
N/A
Profit Margin
-710.60%
Debt to Equity
N/A
Quarterly Earnings Growth YoY
N/A

Adlai Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.00$5.00
Net Profit-$109.23-$51.87-$35.53
Net Profit MarginN/AN/A-710.60%
Income ChangeN/A52.51%31.50%

Adlai Balance Sheet

All figures in USD Million

Particulars202520242023
Non Current Assets7.547.2128.99
Current Assets26.8964.06101.2
Total Assets34.4371.27130.19
Non Current Liabilities1.130.435.47
Current Liabilities41.6345.3649.67
Total Liabilities42.7645.7955.14
Shareholders' Equity-8.3225.4975.05

Adlai Cash Flow

Annually

All figures in USD Million

Particulars202520242023
Operating-33.45-51.82-56.65
Investing-15.5828.07-10.95
Financing-3.81-6.58116.24

About Adlai

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Adlai Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$9.94
$8.59
-10.15%
Oct 2026
$15.72
$9.56
-40.44%
Sep 2026
$13.79
$16.05
+11.92%
Aug 2026
$12.92
$14.34
+10.22%
Jul 2026
$11.33
$13.01
+10.77%
Jun 2026
$12.46
$11.74
-1.72%
May 2026
$13.81
$11.95
-17.44%
Apr 2026
$6.82
$14.47
+109.78%
Mar 2026
$8.19
$6.90
-11.65%
Feb 2026
$8.63
$7.81
-26.04%
Jan 2026
$1.44
$10.56
+654.29%
Dec 2025
$1.54
$1.40
-1.75%

Adlai Share Price FAQs